

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
ACCEPTANCE OF THE SUPPLEMENTAL DRUG APPLICATION
FOR MENHYCIA®

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated December 29, 2021 in relation to the new drug approval granted to the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (“**MCV4**”, trade name: Menhycia®) by the National Medical Products Administration of the People’s Republic of China (the “**NMPA**”).

The Company is pleased to announce that, the Company has obtained the Acceptance Notice (《受理通知書》) issued by NMPA, pursuant to which, the supplemental application to expand the age range of applicable population of MCV4 from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” (the “**Supplemental Application**”) has been accepted by NMPA.

The Company’s Menhycia® is the first MCV4 vaccine product in China. Its launch has narrowed the gap between China and developed countries in this field and filled the gap of China’s lack of high-end vaccines in this field, and provided a better solution for the prevention of infant meningococcal meningitis. MCV4 exerted the advantage of exclusive competitive products, and the Company continued to advance the commercialisation of meningococcal vaccines products, realizing a rapid growth of revenue from sales of meningococcal vaccines. In the first three quarters of 2024, the Group recorded a revenue of RMB516 million from the sales of meningococcal vaccines products, representing an increase of 39.07% compared with the revenue from the sales of meningococcal vaccines products during the corresponding period of 2023.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 26, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.